Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Utah Medical Products (UTMD) EBITDA (2016 - 2025)

Utah Medical Products has reported EBITDA over the past 16 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put EBITDA at $2.9 million for Q4 2025, up 226.7% from a year ago — trailing twelve months through Dec 2025 was $13.8 million (up 9.14% YoY), and the annual figure for FY2025 was $13.8 million, up 9.13%.
  • EBITDA for Q4 2025 was $2.9 million at Utah Medical Products, up from $2.3 million in the prior quarter.
  • Over the last five years, EBITDA for UTMD hit a ceiling of $6.9 million in Q4 2022 and a floor of $884000.0 in Q4 2024.
  • Median EBITDA over the past 5 years was $3.4 million (2021), compared with a mean of $3.6 million.
  • Biggest five-year swings in EBITDA: soared 329.81% in 2021 and later crashed 84.29% in 2024.
  • Utah Medical Products' EBITDA stood at $4.1 million in 2021, then surged by 67.53% to $6.9 million in 2022, then dropped by 19.0% to $5.6 million in 2023, then crashed by 84.29% to $884000.0 in 2024, then skyrocketed by 226.7% to $2.9 million in 2025.
  • The last three reported values for EBITDA were $2.9 million (Q4 2025), $2.3 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.